UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
After an IRA rollover, selecting the right index fund matters for long-term growth and risk management. Compare options and choose confidently.
26,327 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Once-skeptical of SaaS valuations, this longtime saas bear now highlights real value in beaten-down software. He shar...
Iran carried out the executions of a 19-year-old star wrestler and two others, sparking investor worry about sanction...
Bitcoin rebounds into the $70k-$80k zone, but pandemic-style health headlines loom over the market. Traders weigh whe...
PayPal has faced headwinds as AI mania swells elsewhere. This guide breaks down whether paypal stock cheap ignore? is...
Rate Insurance's 2026 Trends Report shows 2025 home premiums rose 9.16%, the first notable slowdown after years of do...
Dell Technologies has moved from the shadows into the AI spotlight. This guide explains why the stock is drawing atte...
Danish biotech Zealand Pharma saw its stock slide after disclosing a 20% dropout rate in its weight-loss drug trial d...
Investors are weighing the fate of the retiring cruise ship dream as the cruise industry rebounds. The reality check:...
ETH struggles to reclaim the $1,900 level as the week closes, while XRP, ADA, BNB, and HYPE carve mixed paths. Trader...
The high-cost DC release posted a weak opening and was trimmed after screenings, fueling questions about DC Studios’ ...
Bitcoin trades around $63,000 as a viral altcoin skyrockets daily, up 80% in 24 hours, driving buzz across traders an...